Nucresiran

DRUG2 trials

Sponsors

Alnylam Pharmaceuticals

Conditions

Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyTransthyretin Amyloidosis With CardiomyopathyhATTR-PN

Phase 3

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

RecruitingNCT07052903

Alnylam PharmaceuticalsTransthyretin Amyloidosis With Cardiomyopathy

Start: 2025-07-02End: 2032-11-30Target: 1750Updated: 2026-09-16

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

RecruitingNCT07223203

Alnylam PharmaceuticalshATTR-PN, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy

Start: 2026-02-03End: 2031-06-12Target: 125Updated: 2026-09-15